Parkinson’s Disease Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Parkinson’s Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Parkinson’s Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Parkinson’s disease. It projects the future incidence and prevalence rates of Parkinson’s disease cases across various populations.  The study covers age, gender, and type as major determinants of the Parkinson’s Disease population. The report highlights patterns in the prevalence of Parkinson’s disease over time and projects future trends based on multiple variables.

Parkinson’s Disease Understanding: Disease Overview

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopamine producing neurons in the substantia nigra. It leads to hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability, often accompanied by nonmotor features such as sleep disturbance, mood changes, and cognitive impairment. PD typically emerges after age 60, although younger onset cases occur. The disease burden increases with aging populations worldwide. The exact cause remains unknown, with contributions from genetic susceptibility and environmental exposures. PD significantly affects quality of life and functional independence.

Parkinson’s Disease Epidemiology Perspective

The Parkinson’s disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Parkinson’s Disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Parkinson’s Disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the Global Burden of Disease Study 2021, approximately 11.77 million people worldwide were living with Parkinson's disease, marking a 274% rise from 3.15 million cases reported in 1990.
• As per the BMJ Open 2025, Parkinson's disease accounted for approximately 1.34 million new incident cases globally in 2021, with the age-standardized incidence rate climbing from 11.24 to 15.63 per 100,000 since 1990.
• According to the Global Burden of Disease Study, Parkinson's disease primarily affects adults aged 65 and above, with the 80+ age group recording the sharpest global rise in incident cases.
• As per the Lancet Healthy Longevity, Parkinson's disease is more prevalent in males (1.54 per 1,000) than females (1.49 per 1,000), with the gender difference reversing among women aged 85 and above.
• According to The Lancet 2024, ethnic differences in Parkinson's disease risk are evident within countries, with disparities potentially reflecting differential access to neurological healthcare across racial and ethnic populations.

Read more about this report - Request a Free Sample

Country-wise Parkinson’s Disease Epidemiology

The Parkinson’s disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the covered countries, the United States presents the highest burden, with the Parkinson's Foundation estimating over 1.1 million Americans living with Parkinson's disease and approximately 90,000 new diagnoses annually. According to the German Burden of Disease Study, in 2022, the prevalence of Parkinson's disease in Germany was 0.35% of the population, representing approximately 295,000 people. The United Kingdom reflects a growing prevalence aligned with its aging population. Japan records the lowest global age-standardized incidence rate at 7.28 per 100,000.  India carries approximately 0.58 million cases, with persistent underdiagnosis due to limited specialist access.

Parkinson’s Disease: Treatment Overview

Treatment for Parkinson’s disease focuses on symptom management and maintaining quality of life, as no cure currently exists. The cornerstone is dopaminergic therapy, primarily levodopa combined with carbidopa to replenish deficient dopamine and reduce motor symptoms. Adjunctive medications such as dopamine agonists and MAO B inhibitors help extend benefit or target specific symptoms. Physical, occupational, and speech therapies support mobility and daily functioning. In selected patients with advanced motor complications, deep brain stimulation can reduce fluctuations and dyskinesias. Treatment is individualized, balancing benefits against side effects over disease progression.

Key Questions Answered

• What are the key findings of Parkinson’s disease epidemiology in the 8 major markets?
• What will be the total number of patients with Parkinson’s disease across the 8 major markets during the forecast period?
• What was the country-wise Parkinson’s disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of Parkinson’s disease patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of Parkinson’s disease during the forecast period of 2026-2035?
• What are the currently available treatments for Parkinson’s disease?
• What are the disease risks, signs, symptoms, and unmet needs of Parkinson’s disease?

Scope of the Parkinson’s Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Parkinson’s disease based on several factors.
• Parkinson’s Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Parkinson’s disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Parkinson’s Disease Market

Parkinson’s Disease Related Dementia Epidemiology Forecast